Our study found that PKM2 or GP73 attenuates the anti-tumor effect of sorafenib, suggesting that searching for specific PKM2 or GP73 inhibitors and combining them with sorafenib may be an effective treatment for HCC. This evidence concerns the gene PKM and hepatocellular carcinoma.